John Wallbillich - Concepedia

Author

John Wallbillich

The Ohio State University Wexner Medical Center ORCID

Also Known As

J J Wallbillich, J. J. Wallbillich, J. Wallbillich, J.J. Wallbillich, John J Wallbillich, John J. Wallbillich, John Wallbillich

Publications

905

Citations

H-Index

Concepts

All Affiliations

The Ohio State University Wexner Medical Center The Barbara Ann Karmanos Cancer Institute The University of Texas MD Anderson Cancer Center Augusta University Health Wayne State University

About

John Wallbillich is an author at The Ohio State University Wexner Medical Center specializing in medicine, oncology, and ovarian cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	652
2	Public Health	2	2	55
3	Cell Biology	2	2	409
4	Immunology	2	2	28
5	Health Sciences	1	1	17

John Wallbillich

Publications

759

Citations

H-Index

Page 1

	Year	Citations
Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins Kalpana Deepa Priya Dorayappan, Ross Wanner, John Wallbillich, Oncogene Novel MechanismSignaling PathwayHypoxia-induced ExosomesMedicineStat3/rab Proteins	2018	297
Vulvar intraepithelial neoplasia (VIN 2/3): Comparing clinical outcomes and evaluating risk factors for recurrence John Wallbillich, H.E. Rhodes, A. Milbourne, Gynecologic Oncology Surgical OncologyVulvar DiseasesGynecological SurgeryGenitourinary CancerVulvar Intraepithelial Neoplasia	2012	118
Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target U. Saini, Srikanth I. Naidu, Adam C. ElNaggar, Oncogene Oncogenic AgentMedicinePromotes InvasionTumor SuppressorStat3 Expression	2016	112
Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix Anthony B. Costales, Andrea Milbourne, Helen Rhodes, Gynecologic Oncology Residual DiseaseCervical Cancer ManagementCancer RiskPrecancerous LesionsCervical Cancer	2013	44
High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer John Wallbillich, Srirama Josyula, Uksha Saini, PLoS ONE	2017	39
<i>STAT3/PIAS3</i> Levels Serve as “Early Signature” Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube Uksha Saini, Adrian A. Suarez, Shan K. Naidu, Cancer Research	2018	21
Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma John Wallbillich, Robert Morris, Rouba Ali‐Fehmi Gynecologic Oncology Uterine Serous CarcinomaGenetic TestingHomologous Recombination GenesMutation FrequenciesSomatic Variant	2020	20
A personalized paradigm in the treatment of platinum-resistant ovarian cancer – A cost utility analysis of genomic-based versus cytotoxic therapy John Wallbillich, Braxton Forde, L.J. Havrilesky, Gynecologic Oncology MedicineCost Utility AnalysisCancer ManagementClinical TrialsGynecology	2016	17
The Genomic Landscape of Vulvar Squamous Cell Carcinoma Logan Corey, John Wallbillich, Sharon Wu, International Journal of Gynecological Pathology Cancer PathologyGeneticsImmunologyPathologyTumor Biology	2023	17
Vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide (VPCBAE) in the management of three patients with small-cell carcinoma of the ovary John Wallbillich, Alpa M. Nick, Pedro T. Ramírez, Gynecologic Oncology Case Reports Tumor BiologyEndocrine OncologyTumoral PathologyMedicineHypercalcemic Type	2012	16

Page 1